GridAI Technologies (GRDX) Stock Price

GridAI Technologies Price

NYSE·CLOSED
4.45
​
Market closed

GridAI Technologies stock price

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

GridAI Technologies business model & stock analysis

First Wave BioPharma Inc is a US-based company operating in Biotechnology industry. The company is headquartered in Boca Raton, Florida and currently employs 10 full-time employees. The company went IPO on 2016-10-11. First Wave BioPharma, Inc. is a clinical-stage biopharmaceutical company. The firm is engaged in the research and development of targeted, non-systemic therapies for the treatment of patients with gastrointestinal (GI) diseases. The company is focused on developing its pipeline of gut-restricted GI clinical drug candidates, including the biologic adrulipase, a recombinant lipase enzyme designed to enable the digestion of fats and other nutrients, and niclosamide, which is an oral small molecule with anti-viral and anti-inflammatory properties. Its adrulipase programs are focused on the development of an oral, non-systemic, biologic capsule for the treatment of exocrine pancreatic insufficiency in patients with cystic fibrosis and chronic pancreatitis. The company is advancing two separate Phase 2 clinical programs of its niclosamide formulations, including FW-COV for Severe Acute Respiratory Syndrome Coronavirus 2 GI infections, and FW-UP for ulcerative proctitis and ulcerative proctosigmoiditis.

Frequently asked questions about GridAI Technologies

6 analysts currently rate the GridAI Technologies stock: 0 recommend buying, 3 holding and 3 selling. For 2026, analysts expect GridAI Technologies to generate revenue of 22.27 M USD and earnings per share of -4.15 USD.

Converted at the current exchange rate, the GridAI Technologies share trades at 3.96 EUR (4.45 USD).

The expected revenue of GridAI Technologies is 22.27 M USD. This figure is based on current financial data and reflects the company's business performance.

The expected profit of GridAI Technologies is -17.54 M USD. The net profit reflects the company's profitability after deducting all expenses.

The price-to-earnings ratio (P/E) of GridAI Technologies is currently -1.07. The P/E ratio compares the current share price to the earnings per share and helps investors assess the valuation of the GridAI Technologies stock.

The price-to-sales ratio (P/S) of GridAI Technologies is currently 0.84. The P/S ratio compares the market capitalization to the annual revenue and serves as a valuation metric for the GridAI Technologies stock.

The Eulerpool Quality Score for GridAI Technologies is 3/10.

The ISIN of GridAI Technologies is US33749P5070. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.

The ticker of GridAI Technologies is GRDX. The ticker symbol is used to trade GridAI Technologies shares on the stock exchange.

Fair ValueTerminal
4.36 USD
Over-/UndervaluationTerminal
Fairly valued
Sector
Industry
Biotechnology
Number of shares
Employees
Revenue per Employee
3,625.10 USD
Revenue growth Ø5 years
EBIT growth Ø5 years
Net Income growth Ø5 years
Currency
USD
Initial public offering
Oct 11, 2016
ISIN
US33749P5070
Cusip
33749P408
Market capitalization
14.95 M USDMicro Cap
52-Week Range
PEG
—
P/E ratio
P/Ee 2026
-1.07
P/Ee 2027
-1.13
P/Ee 2028
3.30
P/Se
0.84
EV/EBIT
—
P/B Ratio
0.63
ROE (Return on Equity)
ROA (Return on Assets)
ROCE (Return on Capital Employed)
ROIC (Return on Invested Capital)
-24.61 %
Last updated Oct 21, 2026, 9:23 PM

GridAI Technologies Peer Group